First Solar Doubles Down on US Manufacturing Amid Strategic Pivot

First Solar launches new US factory to cut Asian reliance, despite missing Q4 earnings and issuing 2026 revenue guidance below analyst estimates.

First Solar is accelerating its domestic production strategy, commencing commercial operations of its latest module generation within the United States. This move, centered on a new 3.7-gigawatt facility, is designed to lessen reliance on Asian supply chains and capitalize on substantial federal tax incentives. The strategic expansion comes at a pivotal moment for the company, which faces heightened scrutiny following a recent earnings report that fell short of market expectations.

Earnings Context and Cautious Guidance

The company’s strategic shift follows a period of stock market volatility triggered by its latest financial results. For the fourth quarter of 2025, First Solar reported earnings per share of $4.84, missing analyst estimates of $5.19. While the firm achieved a record annual revenue of $5.2 billion for the full 2025 fiscal year, its outlook for 2026 remains measured.

Management has provided revenue guidance for the full year 2026 in a range of $4.9 billion to $5.2 billion. This forecast is notably below the $6.1 billion anticipated by market analysts. The company cites declining average selling prices and the intentional underutilization of its international manufacturing capacity as primary reasons for this conservative projection. A significant financial buffer is expected from Section 45X manufacturing tax credits, which could amount to approximately $2.1 billion in 2026.

Should investors sell immediately? Or is it worth buying First Solar?

Series 7 Modules and Domestic Supply Chain Focus

The cornerstone of this US-focused strategy is the new Series 7 thin-film module, now deployed at the Dodson Creek solar project in Ohio. This technology is central to the company’s operational plans for the current year and is projected to eventually represent over two-thirds of its US production capacity. In a parallel effort, First Solar is advancing construction on a new finishing facility, a step that repatriates final assembly processes from Southeast Asia back to American soil.

This calculated repositioning is a direct response to current US industrial policy, which strongly incentivizes local supply chains. By manufacturing domestically, the company aims to navigate international trade tariffs while maximizing its eligibility for government subsidies and incentives.

Key Upcoming Dates for Investors

Shareholders should mark several important dates on the calendar. The annual shareholder meeting will be held virtually on May 13. The agenda includes the election of ten directors, votes on executive compensation, and a shareholder proposal focused on simplifying the process for calling special meetings. Shareholders of record as of March 19 are eligible to vote.

First Solar is scheduled to release its first-quarter 2026 results in late April. Market experts currently anticipate earnings per share around $2.84 for this period. Another critical deadline is July 4, 2026. By this date, project developers must secure capacity to qualify for existing tax credit provisions. This cutoff is likely to significantly influence the company’s order backlog during the second half of the year.

Ad

First Solar Stock: New Analysis – 5 April

Fresh First Solar information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated First Solar analysis…

Source link

First Solar Doubles Down on US Manufacturing Amid Strategic Pivot

First Solar launches new US factory to cut Asian reliance, despite missing Q4 earnings and issuing 2026 revenue guidance below analyst estimates.

First Solar is accelerating its domestic production strategy, commencing commercial operations of its latest module generation within the United States. This move, centered on a new 3.7-gigawatt facility, is designed to lessen reliance on Asian supply chains and capitalize on substantial federal tax incentives. The strategic expansion comes at a pivotal moment for the company, which faces heightened scrutiny following a recent earnings report that fell short of market expectations.

Earnings Context and Cautious Guidance

The company’s strategic shift follows a period of stock market volatility triggered by its latest financial results. For the fourth quarter of 2025, First Solar reported earnings per share of $4.84, missing analyst estimates of $5.19. While the firm achieved a record annual revenue of $5.2 billion for the full 2025 fiscal year, its outlook for 2026 remains measured.

Management has provided revenue guidance for the full year 2026 in a range of $4.9 billion to $5.2 billion. This forecast is notably below the $6.1 billion anticipated by market analysts. The company cites declining average selling prices and the intentional underutilization of its international manufacturing capacity as primary reasons for this conservative projection. A significant financial buffer is expected from Section 45X manufacturing tax credits, which could amount to approximately $2.1 billion in 2026.

Should investors sell immediately? Or is it worth buying First Solar?

Series 7 Modules and Domestic Supply Chain Focus

The cornerstone of this US-focused strategy is the new Series 7 thin-film module, now deployed at the Dodson Creek solar project in Ohio. This technology is central to the company’s operational plans for the current year and is projected to eventually represent over two-thirds of its US production capacity. In a parallel effort, First Solar is advancing construction on a new finishing facility, a step that repatriates final assembly processes from Southeast Asia back to American soil.

This calculated repositioning is a direct response to current US industrial policy, which strongly incentivizes local supply chains. By manufacturing domestically, the company aims to navigate international trade tariffs while maximizing its eligibility for government subsidies and incentives.

Key Upcoming Dates for Investors

Shareholders should mark several important dates on the calendar. The annual shareholder meeting will be held virtually on May 13. The agenda includes the election of ten directors, votes on executive compensation, and a shareholder proposal focused on simplifying the process for calling special meetings. Shareholders of record as of March 19 are eligible to vote.

First Solar is scheduled to release its first-quarter 2026 results in late April. Market experts currently anticipate earnings per share around $2.84 for this period. Another critical deadline is July 4, 2026. By this date, project developers must secure capacity to qualify for existing tax credit provisions. This cutoff is likely to significantly influence the company’s order backlog during the second half of the year.

Ad

First Solar Stock: New Analysis – 5 April

Fresh First Solar information released. What’s the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated First Solar analysis…

Source link

Democratic Senators Call on Trump to Block Chinese Automakers From Manufacturing in U.S.

By Elias Schisgall

Three Democratic senators called on President Trump to crack down on the manufacturing and sales of Chinese vehicles in the U.S.

Democratic Sens. Tammy Baldwin of Wisconsin, Elissa Slotkin of Michigan, and Minority Leader Chuck Schumer of New York wrote a letter to Trump also calling for a ban on Chinese vehicles manufactured or titled in Canada and Mexico from entering the U.S.

They additionally argued against letting Chinese automakers open factories in the U.S. and said the administration should work with allies to “address the serious threat posed by Chinese vehicles.” They said the U.S. should support American automakers and their supply chains, adding that Chinese high-tech vehicles could pose a national security risk.

“We urge you to stay the course and make it clear that Chinese auto manufacturers and their products present unprecedented dangers to our economic and national security, and their manufacture, sale, or operation on U.S. soil is non-negotiable,” the senators wrote.

The letter follows Trump’s suggestion at a January meeting of the Detroit Economic Club that despite the administration’s trade tensions with China, he was open to Chinese automakers making investments in the U.S.

“If they want to come in and build a plant and hire you and hire your friends and your neighbors, that’s great, I love that,” Trump said during the event. “Let China come in.”

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

04-03-26 1214ET

Source link

Samsung Biologics establishes first U.S. manufacturing base with acquisition of GSK site – Chemical Engineering

April 3, 2026 | By Mary Bailey

Samsung Biologics, a leading contract development and manufacturing organization (CDMO), announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States.

The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-liter drug substance capacity, supporting both clinical and commercial biologics production across multiple manufacturing scales. With this addition, Samsung Biologics’ total global manufacturing capacity increases to 845,000 liters.

Samsung Biologics will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement, and the site will transition to serve additional contract manufacturing needs. Samsung Biologics also plans further investments to expand the site’s capacity and upgrade technologies, reinforcing its long-term commitment to advancing a more resilient global supply chain and improving patient access to critical medicines.

“This represents a meaningful step in expanding our U.S. manufacturing footprint. The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network, and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family,” said John Rim, President and CEO of Samsung Biologics. “The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network. As a CDMO, our mission is to help our partners bring important therapies to patients worldwide, and this site will play a pivotal role in that mission while ensuring continuity and upholding the high standards our clients expect.”

The completion follows the previously announced agreement to acquire the facility on December 22, 2025.

Source link

Trump Pharma Tariffs: Wrong Rx for U.S. Patients, Manufacturing, and Innovation | Blogs | Apr 3, 2026

Concluding a Section 232 investigation into pharmaceuticals launched last year, the Trump administration has announced it will impose tariffs of up to 100 percent on imports of branded pharmaceutical drugs (generic drugs are exempt). While numerous carveouts, exceptions, and exemptions will apply, the proclamation is misguided for many reasons. Most notably, it will harm both American patients and the nation’s drug innovation capacity, even as the administration’s continued fixation on tariffs overlooks far more effective policies to strengthen U.S. biopharmaceutical manufacturing and innovation. With the right mix of policies, the administration could achieve the increase in domestic drug manufacturing it seeks without the harmful side effects that tariffs would bring.

It should be noted that companies exporting from nations with which the United States has recently completed new trade deals will face capped tariffs—15 percent in the case of the European Union, Japan, South Korea, and Switzerland, and 10 percent for the United Kingdom. Moreover, 17 major drugmakers have already entered into so-called “most-favored nation” (MFN) drug-pricing agreements with the U.S. government that would exempt them from the 100 percent tariff. The announcement also gives companies not covered by a trade agreement or an existing MFN deal 120 days to either announce new or expanded manufacturing facilities in the United States or conclude an MFN agreement with the administration.

Thus, while the top-line 100 percent tariff figure sounds—and is—quite high, the numerous carveouts and exemptions mean the effective tariff rate will likely be lower. Nevertheless, this outcome of the Section 232 pharma investigation is misguided. As ITIF has warned, the tariffs will needlessly harm U.S. patients and, ultimately, U.S. biopharmaceutical innovation.

These tariffs will hit American patients—especially those who depend on innovative medicines from foreign drugmakers—extremely and unnecessarily hard. This is especially true for small firms that make treatments for rare diseases (which affect small patient populations) that simply lack the scale to expand manufacturing operations to the United States. For example, the Japanese companies Ono Pharmaceutical and Kyowa Kirin Co. produce innovative treatments for rare gastrointestinal stromal tumors and rare cutaneous T-cell lymphomas, respectively. Meanwhile, the Indian biopharmaceutical company Biocon produces itolizumab, an innovative biologic treatment for acute psoriasis that inhibits the improper immune response that causes psoriatic blemishes. Elsewhere, in Saudi Arabia, ITIF has highlighted breakthrough research into innovative stem cell treatments for leukemia.

Whether the section 232 tariffs raise prices for critical imported drugs to 15 percent, 100 percent, or to some other level, they will needlessly increase the cost of imported medicines Americans depend on and harm patients who benefit from innovations developed around the world to treat or cure difficult diseases.

Another critical problem with these 232 pharma tariffs is that they further entrench the misguided MFN drug price control regime that, as ITIF has documented, is already inflicting tremendous damage on the U.S. biopharmaceutical innovation system. The Trump administration’s MFN price controls build on the previous administration’s price controls for Medicare Part D drugs introduced in 2022 through the Inflation Reduction Act (IRA).

Studies examining the IRA’s impact have found that since its drug-pricing framework (i.e., the proposed legislation) was first drafted in 2021, venture capital funding for small-molecule research and development (R&D) has fallen by nearly 70 percent. Other studies show that since the IRA’s enactment, the number of clinical trial starts for new, unapproved small-molecule medicines has fallen by 25 percent, while clinical trials for new uses of existing small-molecule medicines have fallen by 30 to 45 percent. Drug price controls weaken drug innovation, and by further entrenching the MFN regime through the threat of tariffs, the administration’s Section 232 pharma tariffs will inflict serious long-term damage on the ability of drug innovators worldwide to earn the returns needed to invest in the R&D required to produce the next generation of cures.

Furthermore, extending the tariffs to intermediate ingredients—such as active pharmaceutical ingredients (APIs) and other key starting materials—will amplify the harm. Manufacturers will face higher input costs at all stages of production, not just at the final point of sale, compounding cost pressures across the supply chain. Unlike tariffs on finished branded drugs, which primarily affect the price of the final product, new tariffs on APIs raise costs for all manufacturers that rely on those ingredients, including producers of medicines not themselves subject to the tariff. This approach risks creating supply chain disruptions and price pressures beyond the intended scope of the policy, particularly given that the production of certain critical ingredients is concentrated among a few suppliers.

Finally, U.S. drug manufacturers could be harmed if other nations respond by raising their tariffs to match these newly announced U.S. rates, thus harming exports of American drugs.

If the Trump administration seeks to increase drug manufacturing in the United States—a desirable goal—it should pursue this objective in ways that don’t unnecessarily harm American patients or long-term biopharmaceutical innovation. ITIF has highlighted a wide range of proactive policies that could achieve these aims without the harmful side effects of tariffs.

One approach to strengthen biopharmaceutical R&D and manufacturing while addressing systemic cost pressures would be to expand public-private partnerships that accelerate technological innovation. For example, the National Science Foundation (NSF) could increase support for university-industry research centers working on biopharma production technology and potentially establish new centers. Policymakers should also create an additional Manufacturing USA Institute alongside the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to focus on manufacturing innovations for APIs and generic drugs.

The Trump administration’s Section 232 pharma tariffs will harm patients and both American and global drug innovators—a remedy far worse than the disease. These tariffs should be fully rescinded.

Source link

Trump announces tariffs as high as 100% on pharmaceuticals

Exemptions include generic drugs and companies that have committed to building manufacturing plants in the United States.

President Donald Trump has announced a new pharmaceutical tariff that would impose as much as 100% on imported brand-name drugs. 

The executive order, announced Thursday, is to spur the production of pharmaceuticals in the United States. 

Exemptions are for generic drugs and companies that have already pledged to build manufacturing facilities in the United States. Pharma companies that lower prices would be subject to a 20% tax. 

“I have determined that it is necessary and appropriate to impose a 100 percent ad valorem duty rate on the import of patented pharmaceuticals and associated pharmaceutical ingredients …” Trump said in Thursday’s proclamation. “I have determined that it is necessary and appropriate that the ad valorem duty rate be 20 percent on imports of patented pharmaceuticals and associated pharmaceutical ingredients produced by companies that have plans, approved by the Secretary, to onshore production of such pharmaceuticals and pharmaceutical ingredients.”

The 20% rate will increase to 100% four years after the date of the proclamation, Trump said.

No tariffs would be imposed on imports of patented pharmaceuticals and associated pharmaceutical ingredients produced by companies that have fully executed agreements or are negotiating agreements with the Secretary and the Secretary of Health and Human Services regarding Most Favored Nation pricing and onshoring of production.

“Such agreements further United States economic and national security interests by making pharmaceuticals more accessible and affordable in the United States and by strengthening the domestic manufacturing base,” Trump said.

Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl responded by statement: “Tariffs on cutting-edge medicines will increase costs and could jeopardize billions in U.S. investments announced in the last year. Every dollar spent on tariffs is a dollar that can’t be invested in communities across the country. 

“The innovative biopharmaceutical sector has a robust U.S. manufacturing footprint. In fact, two-thirds of the medicines that are consumed in the U.S. are made in America. And when innovative medicines or their inputs are sourced from other countries, these products overwhelmingly come from reliable U.S. allies, like Europe and Japan.”

Biopharmaceutical innovation has delivered $1.7 trillion in economic impact, supported 5 million American jobs and provided patients with the access to new medicines, he said.

Email the writer: [email protected]

 

Source link

US manufacturing performance improves in March 2026

US manufacturing performance improved in March this year, with growth solid and picking up since February amid better gains in both output and new orders, according to S&P Global US Manufacturing purchasing managers’ index (PMI) data.

The seasonally-adjusted S&P Global US manufacturing PMI recorded 52.3 in March. That was an improvement from 51.6 in February and indicative of a moderate rate of expansion. It was the eighth successive month that the PMI has posted above the critical 50 no-change mark.

However, with tariffs continuing to hit new export sales, US growth was principally driven by higher domestic demand. Moreover, this in part reflected some client safety stock building due to the war in the Middle East, which drove up inflation and added to supply-chain stress.

US manufacturing performance improved in March, with growth solid and picking up since February amid better gains in both output and new orders, S&P Global US manufacturing PMI data show.
However, with tariffs continuing to hit new export sales, US growth was principally driven by higher domestic demand.
Firms are hopeful that March’s overall increase in sales will be sustained over the coming months.

March’s survey signalled notable accelerations in both input and output price inflation, whilst the time taken to deliver inputs to manufacturers deteriorated to the greatest degree since October 2022, a release from S&P Global said.

Meanwhile, confidence in the outlook softened fractionally, with firms noting worries over higher energy prices and tariffs.

Employment numbers were little changed overall.

Higher output and new orders helped to support the PMI in March. In both instances, growth rates were solid.

Firms are hopeful that March’s overall increase in sales will be sustained over the coming months. Confidence in the outlook remained positive overall.

However, worries over energy prices and tariffs meant expectations softened slightly since February.

Heightened uncertainty in the outlook prompted some firms to build safety stocks, resulting in strong growth in purchasing activity. Overall buying rose at one of the fastest rates since June 2025, though input inventories remained unchanged in March.

Firms adopted a more cautious approach to hiring, with staffing levels largely unchanged. Meanwhile, vendor delivery times deteriorated to the greatest extent in nearly three-and-a-half years, as the war in the Middle East disrupted transportation and worsened supplier stock shortages.

The conflict also pushed up global energy prices, adding to cost pressures. In response, firms raised their selling prices where possible, driving factory gate inflation to a seven-month high in March.

Fibre2Fashion News Desk (DS)

Source link

Trump Praises Nissan’s Move to Boost U.S. Manufacturing

President Donald Trump on Wednesday publicly cheered Nissan’s push to shift more vehicle production to the United States, crediting tariff pressure and singling out Nissan Americas chairman Christian Meunier by name. Nissan has told investors and reporters that it has sharply increased the share of cars sold in the U.S. that are built domestically, is planning to roll out new hybrid technology within roughly 18 months, and is retooling its Canton, Mississippi, plant for electric-vehicle production. All of that is happening while the company pursues a global recovery plan that will cut capacity and jobs worldwide.

Trump’s public shout-out

Trump took to Truth Social to weigh in, writing, “Wow! Congratulations to Nissan, and Christian Meunier, Americas Chairman, on the tremendous success they are having in the U.S….” as reported by the Denver Gazette. The post landed shortly after comments from Nissan executives and was quickly picked up by national business outlets, framing the automaker’s moves as a validation of the administration’s trade playbook.

What Nissan executives are saying

In a Fox Business interview, Meunier said tariffs have reshaped the math for automakers, arguing they are “really pushing all the manufacturers to do the right thing, which is really to build locally and to sell in the U.S.” He said Nissan has lifted the share of U.S.-sold vehicles that are made domestically from about 45% a year ago to more than two-thirds today, with a target of roughly 80%. Meunier added that the company expects to launch new hybrid technology within the next 18 months and that it plans to expand hiring tied to its U.S. production buildout.

Canton retooling and a U.S. battery pact

Nissan has committed approximately $500 million to retool its Canton Assembly Plant in Mississippi for electric-vehicle production, a serious upgrade for a site that has long been a major regional employer. The company has also lined up a battery-supply deal that will send U.S.-manufactured cells to vehicles built there.

The SK On agreement and Nissan’s description of the Canton investment were laid out in a company release published via BusinessWire. The pact is described as supporting roughly 1,700 jobs at the battery supplier, with U.S.-made cells slated for the Canton line starting in 2028.

Restructuring, plant closures and job cuts

Those new U.S. dollars are part of a far more sobering global picture. Nissan’s Re: Nissan restructuring plan calls for consolidating production and shrinking its global headcount in an effort to restore profitability. Industry reporting indicates the company plans to reduce its number of plants from 17 to 10 and to cut roughly 20,000 positions worldwide as part of the plan, according to coverage by WardsAuto.

The Associated Press has also reported on the reductions and noted that trade-policy shifts, including recent tariffs, have been a material factor in Nissan’s financial results.

Policy backdrop: tariffs and incentives

The administration’s mix of tariffs and incentives is designed to reshape where and how automakers invest. The policy package includes offsets and other adjustments intended to nudge companies toward U.S. assembly plants and domestic supply chains rather than overseas production. The White House laid out that framework in a fact sheet that describes how the measures are meant to boost domestic manufacturing and U.S.-based jobs.

For communities from Canton to supplier towns around the Nashville area, the combination of fresh EV investment and sweeping global downsizing creates a complicated local reality. Nissan employs roughly 20,000 people in the United States, a figure cited in national coverage of the company’s recent remarks and plans, and local hiring tied to new battery and EV lines could offset some losses depending on which facilities are retooled and which are shut down. In the coming months, industry watchers will be tracking production timetables, hybrid rollouts, and Nissan’s list of specific plant changes to see how those trade-offs land on the ground.

Source link

Samsung Biologics secures first manufacturing base in U.S.

사진 확대 (Samsung Biologics)

Samsung Biologics Co. has expanded its global production network by securing its first manufacturing base in the United States.

Samsung Biologics announced on Wednesday that it completed the acquisition of a biopharmaceutical production facility in Rockville, Maryland, previously owned by GSK Plc, as of Tuesday, local time. The deal was carried out through its subsidiary, Samsung Biologics America.

The Rockville site is a drug substance (DS) manufacturing plant with total capacity of 60,000 liters, comprising two production buildings. It is equipped with infrastructure capable of producing antibody therapeutics at various scales, from clinical-stage to commercial production.

With this acquisition, Samsung Biologics has expanded its total production capacity to 845,000 liters from 785,000 liters. The company said that it has now established a dual production system connecting Songdo, Korea, and Rockville, enabling more stable and flexible supply to global clients.

In particular, securing a production base in North America is expected to strengthen responsiveness to local customers and further enhance competitiveness in winning global contracts.

Samsung Biologics has retained all approximately 500 employees at the Rockville facility, ensuring operational continuity. It plans to pursue stable supply of existing products while expanding new orders through integrated operations between the two production bases.

The company said it will also review further investment, including capacity expansion and technology upgrades at the Rockville facility, based on mid- to long-term demand and utilization.

“This represents a meaningful step in expanding our U.S. manufacturing footprint,” said John Rim, president and chief executive officer of Samsung Biologics. “The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network.”

By Wang Hae-na and Chang Iou-chung
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]

Source link

Quartz Manufacturing Alliance of America Commends ITC for Affirmative Injury Determination in Global Safeguard Case

WASHINGTON, April 1, 2026 /PRNewswire/ — The Quartz Manufacturing Alliance of America (QMAA) today commended the U.S. International Trade Commission (ITC) for its affirmative injury determination in the Global Safeguard petition filed by the coalition in September. The affirmative determination signifies the ITC’s recognition of the serious injury caused by a surge of quartz surface imports entering the United States from around the globe.

QMAA Logo

“Today’s ITC injury determination is a great step forward for American quartz manufacturing and the 100,000 American jobs this industry supports,” remarked Luke Meisner, Counsel for QMAA. “With foreign quartz imports representing nearly 90% of the U.S. market, we are confident that the ITC will recommend that the President take decisive action in the coming weeks.”

“We applaud today’s ITC injury determination that recognizes the negative impact of the flood of foreign quartz surface products coming into our country,” said Cambria CEO Marty Davis. “These quartz imports don’t just put slab manufacturers at risk, they also steal business from downstream American fabricators. Now is the time to stop the cheating. Free and fair trade, and a level playing field is all that U.S. manufacturers desire.”

“Today, when I walk through the plant, I see uncertainty and fear in the eyes of employees who worry they may be next to be let go,” remarked Daniel Vaz De Melo Sa, Business Development Manager of Guidoni USA. “The ITC’s injury determination marks significant progress towards saving this great American manufacturing industry.”

“Our industry is at risk without safeguard measures in place,” remarked Michael Morici, Vice President of Surfaces at LX Hausys America. “Thanks to the ITC’s vote, we are one step closer to saving American quartz jobs and remain committed to reinvestment and growth.”

The domestic quartz manufacturing industry supports over 100,000 American jobs across the country. These jobs are in jeopardy due to the flood of unfairly traded imports from nations such as India, Thailand, Vietnam, and Malaysia, which is why QMAA filed a Global Safeguard petition to initiate this case.

About the Quartz Manufacturing Alliance for America
QMAA is a coalition of U.S.-based, American quartz slab manufacturing factories, united with other industry leaders to support and strengthen the American quartz industry. QMAA is committed to ensuring a free and fair, competitive marketplace born of free enterprise that provides the opportunity to compete on a level playing field for American quartz slab manufacturing factories and their valued workers. We also believe this effort will have a positive impact throughout the entire quartz surfacing industry, including to the strong benefit of American stone fabrication shops and upstream suppliers of quartz minerals and resin. Learn more at: https://www.qmaa.org/

Source link